This first module in the series of Breaking the Monoamine Barrier will focus on describing the limitations of conventional monoaminergic antide
Supported by an educational grant from Axsome Therapeutics, Inc.
All Education
In the final module of Breaking the Monoamine Barrier, Craig Chepke discusses how to make informed treatment decisions regarding glutamatergic antidepressants for patients with MDD on the basis of
Assess the latest clinical data associated with the efficacy, tolerability, and safety of glutamatergic antidepressants for MDD in this third module of Breaking the Monoamine Barrier
In Module 2 of Breaking the Monoamine Barrier, Dr.